← Back to Clinical Trials
Recruiting NCT06648954

NCT06648954 Effect of Multisite High-definition Transcranial Direct Current Stimulation Targeting Sensorimotor Network

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06648954
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2022-08-13
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
multisite HD-tDCSConventional tDCSSham stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2022-08-13 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Transcranial direct current stimulation (tDCS) has been applied to facilitate cortical excitability in stroke populations, as increasing evidence suggests that clinical recovery from stroke is attributed to neuroplastic reorganization. However, recovery from stroke following this kind of non-invasive neuromodulation remains divergent across stroke patients due to variations in their etiologies, lesion profiles and post-stroke duration. A novel multisite high definition tDCS (HD-tDCS) in healthy people showed that such network-targeted stimulation could enhance motor excitability beyond conventional stimulation which targeting only one region. The electrode placements could be determined by the montage optimization, which targets individual motor network activation navigated by task-based fMRI using computation algorithms. By targeting motor network, the new multisite electrode montage may provide a potential to facilitate better cortical activation than conventional tDCS montage.

Eligibility Criteria

Inclusion Criteria: 1. first-ever stroke, the duration after stroke exceeds 12 months; 2. mild to moderate upper extremity motor function deficit, determined by the Fugl-meyer assessment of upper extremity (FMAUE) scores between 15 and 53; 3. could voluntarily perform grasping hand movement. 4. sufficient cognitive function to follow the assessment and experiment instructions. Exclusion Criteria: 1. history of epilepsy, or any other contradictions of brain stimulation and MRI scanning; 2. severe joint contracture of elbow or shoulder, or pain induced by any other neurological, neuromuscular, and orthopedic diseases.

Contact & Investigator

Central Contact

Raymond Kai-yu Tong, PhD

✉ kytong@cuhk.edu.hk

📞 +852 3943 8454

Principal Investigator

Raymond Kai-yu Tong, PhD

PRINCIPAL INVESTIGATOR

Department of Biomedical Engineering, CUHK

Frequently Asked Questions

Who can join the NCT06648954 clinical trial?

This trial is open to participants of all sexes, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06648954 currently recruiting?

Yes, NCT06648954 is actively recruiting participants. Contact the research team at kytong@cuhk.edu.hk for enrollment information.

Where is the NCT06648954 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT06648954 clinical trial?

NCT06648954 is sponsored by Chinese University of Hong Kong. The principal investigator is Raymond Kai-yu Tong, PhD at Department of Biomedical Engineering, CUHK. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology